Intuitive Announces FDA Clearance of Fifth-Generation Robotic System Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst : Great. And I'll also add my congratulations on the robotic approval. I wanted to ask, there were a number of new features like insufflation and cameras and I'm sure a number of others that used to be third-party add-ons that you're now bringing in-house. How do you think about Intuitive Surgical, taking these in-house? I would imagine you think you could do it better. And how does that add to the procedure revenues that you can see?

Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst : No, I was all done. Go ahead.

Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst : Great. And I appreciate that. Maybe just a quick follow-up. You talked about there's a great resell opportunity for Xi and potentially X, how do we think about the price change for those 2 robots? And you mentioned several contraindications for Xi, how do we think about those more broadly?

Question: Brandon Vazquez - William Blair & Company L.L.C., Research Division - Analyst : Congrats. On the -- one of the more interesting updates I saw was the improvement in processing power up to 10,000 more or x more processing power. I guess the question is, at launch, I assume you're not going to be fully utilizing that power. What can you use that processing power in the future? And what's kind of like the time line of development for some of those new features?

Question: Brandon Vazquez - William Blair & Company L.L.C., Research Division - Analyst : Okay. Great. And maybe one quick follow-up as maybe a little bit of clarification. I know you guys aren't updating or -- the guidance for the year, but maybe as a question of clarification on the guidance you previously provided, was da Vinci 5 launch already contemplated in that prior guidance?